This study aimed to investigate how the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide (LIR) addresses bone metabolism imbalances induced by type-II diabetes. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.